SMOORE
13.10.2021 07:52:07 CEST | Business Wire | Press release
SMOORE, a global leader in offering vaping technology solutions, today announced that its flagship tech brand, FEELM, has received a gold award in the product design category of 2021 MUSE Design Awards for its ultra-slim disposable vape with ceramic coil, TA15. Moreover, FEELM is the only brand winning 2021 MUSE Design Award in the atomization field. The MUSE Design Awards is an international competition for designers whose craftsmanship leads to paradigm shifts.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211012006272/en/
As the world’s first disposable ultra-slim pod product equipped with ceramic coil, TA 15 marks the opening of a new ceramic era of disposable vapes. FEELM atomization coil inside TA 15 guarantees low power consumption, stronger vapor, stable and popping-free vaping experience. Despite its ultra-slim body, TA15 is long-lasting for over 300 puffs.
Moreover, TA15 adopts an anti-condensation structure to control the dynamic condition of e-liquid, lowering the leakage rate to the greatest extend and offering premium user experience.
The slightly arc surface wraps the inner structure compactly forming a 7.5 mm thinnest body. The vertically textured surface makes it comfortable to hold and reduces remains of fingerprints. The raised part of TA 15 prevents the mouthpiece from contact with desk for hygiene and features a concealed air inlet.
Meanwhile, the highlighted “pixel block” is actually a metal sticker, whose color is changed with flavors and support customization.
By virtue of unique design and innovation technology, this product has effectively solved the industry’s pain point of leakage without a silicone plug. Thanks to breakthrough in materials and structural science, there’s no burnt taste, but with more delicate vapor and purer taste, thus delivering an extraordinary vaping experience.
“I always put users first, and attempt to deeply understand and explore their potential needs. Driven by design thinking, we combine practicability and minimalism, highlighting the performance of our ceramic coil while making other parts as thin as possible.” said Qing Ling, ID Designer of TA15.
Since its global launch in 2016, FEELM has a significant impact on the research and manufacturing of closed vaping products and changed the global vaping industry landscape, ushering into a new era of ceramic coil.
The MUSE Design Awards is a part of the MUSE Awards Program, which was created by the International Awards Associate (IAA) in 2015. IAA’s inception was based on a mission to honor, promote and encourage creativity by providing a new standard of excellence for evaluating media design production and distribution. IAA’s mission has largely shaped MUSE Design Awards' goals.
For more information, please visit https://design.museaward.com/winner-info.php?id=6819
About FEELM:
FEELM is a flagship atomization technology brand belonging to SMOORE. Focusing on the research of cutting-edge atomization technology, FEELM also specializes in the development and manufacturing of high-quality atomization devices driven by FEELM coil. “FEELM inside” symbol is on the closed system pods of a number of global leading tobacco companies and vaping companies around the world.
About SMOORE:
SMOORE is a global leader in offering vaping technology solutions, including manufacturing vaping devices, and vaping components, with advanced R&D technology, strong manufacturing capacity, wide-spectrum product portfolio and diverse customer base. The Company is the world's largest vaping device manufacturer in terms of revenue, accounting for 18.9% of the total global market share.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211012006272/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 07:00:00 CET | Press release
The United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults RelabotulinumtoxinA is designed to optimize molecule integrity to deliver fast onset of action as early as Day 1 and sustained results for six months for frown lines and crow’s feet and has been approved in over 20 markets, including in the European Union1-3 Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation
High-end Aesthetic Brand ‘Lorient’ Gains Global Prestige at IMCAS 20261.2.2026 08:00:00 CET | Press release
Lorient, a premium aesthetic brand, announced that it has drawn global attention at the 27th IMCAS World Congress 2026 in Paris, attracting over 15,000 professionals and demonstrating its leadership in aesthetic innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131322203/en/ Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibility (Image: Lorient) The highlight was a session led by Dr. Jani van Loghem, a globally revered key opinion leader known for establishing international aesthetic safety protocols. His involvement provided a prestigious validation of the technical excellence of Lorient. Alongside him, prominent Korean medical experts Dr. Won Lee and Dr. Do Young Rhee shared clinical insights that drew widespread praise from the international medical community. Central to the academic discussions was Lorient’s "safety-first" philosophy for its premium HA filler ran
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
